The PARADIGM of ARNI's: Assessing reasons for non-implementation in heart failure

Mitja Lainscak, Andrew J S Coats

    Research output: Contribution to journalEditorialOtherpeer-review

    8 Citations (Scopus)


    Several trials have targeted neutral endopeptidase to demonstrate benefits for patients with heart failure. In the PARADIGM-HF trial, a combination of sacubitril and valsartan was superior to enalapril in reducing the risk of death and of hospitalization for heart failure. In this editorial we apply the trial to heart failure population at large to estimate what proportion of patients might actually be treated in daily practice.

    Original languageEnglish
    Pages (from-to)187-189
    Number of pages3
    JournalInternational Journal of Cardiology
    Publication statusPublished - 1 Jun 2016

    Cite this